Cisplatin-based Neoadjuvant Chemotherapy in the Treatment of Patients with Advanced Bladder Cancer

龚华,沈兵,谈明岳,范昱

DOI: https://doi.org/10.3969/j.issn.1671-4695.2011.10.015

2011-01-01

Abstract:Objective To investigate the efficacy and toxicity of cisplatin-based combination chemotherapy in patients with advanced bladder cancer.Methods Of the fifty-four patients with advanced bladder cancer,22 patients received neoadjuvant chemotherapy with the regimen of MVAC(methotrexate 30 mg/m2,2 d-1,15 d-1,22 d-1;vinblastine 3 mg/m2,2d-1,15d-1,22d-1;adriamycin 30 mg/m2,2d-1;and cisplatin 70 mg/m2,2d-1);22 patients received neoadjuvant chemotherapy with the regimen of GC(gemcitabine 1000 mg/m2,1d-1,8d-1,15d-1 and cisplatin 70 mg/m2,2d-1);14 patients received neoadjuvant chemotherapy with the regimen of DC(docetaxel 75 mg/m2,1d-1,8d-1,15d-1 and cisplatin 70 mg/m2,2d-1).All patients received neoadjuvant chemotherapy three cycles.Results There were 10 patients CR,17 patients PR,18 patients SD,and 9 patients PD among 54 patients after treatment by neoadjuvant chemotherapy plus cystectomy,the response rate was 50%(27/54).The median time to progression(TTP) was 10.1 months,and median survival time(MST) was 14.8 months.The major toxicity was anemia(48.1% in grade Ⅲ～Ⅳ) and leukopenia(46.3% in grade Ⅲ～Ⅳ).Conclusion Better clinical effects have been achieved in the therapy of advanced bladder cancer by cisplatin-based neoadjuvant chemotherapy plus cystectomy and toxicities are tolerable.